Tacrolimus metabolite cross-reactivity in different tacrolimus assays

Clinical Biochemistry

Volumn 31, Issue 8, 1998, Pages 613-617

  Murthy, Jayasimha N ^a,c   Davis, Diane L ^a,d   Yatscoff, Randall W ^b   Soldin, Steven J ^a,c,d  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d CATHOLIC UNIVERSITY OF AMERICA   (United States)

Author keywords

Cross reactivity; Immunoassay; Immunophilins; Immunosuppression; Radioreceptor assay; Tacrolimus metabolites

Indexed keywords

13 O NORTSUKUBAENOLIDE; 15 O NORTSUKUBAENOLIDE; 31 O NORTSUKUBAENOLIDE; DRUG BINDING PROTEIN; DRUG METABOLITE; IMMUNOPHILIN; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CATTLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG DETERMINATION; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MIXED LEUKOCYTE CULTURE; NONHUMAN; PRIORITY JOURNAL; RADIORECEPTOR ASSAY;

CROSS REACTIONS; IMMUNOASSAY; IMMUNOPHILINS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RADIOLIGAND ASSAY; TACROLIMUS;

EID: 0032420378     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(98)00086-1     Document Type: Article

References (26)

1. Przepirorka D. Tacrolimus: preclinical and clinical experience. In: Recent development in transplantation medicine. Vol 1. (Eds. Sollinger H, Przepirorka D), Pp. 29-50. Glenview, IL: Physicians & Scientists Publishing Co., 1994.
2. Suthanthiran M., Morris R.E., Strom T.B. Immunosuppressants cellular and molecular mechanisms of action . Am J Kidney Dis. 28:1996;159-172.
3. Clipstone N.A., Crabtree G.R. Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporine A and FK506. Ann N Y Acad Sci. 696:1993;20-30.
4. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol Today. 13:1992;136-142.
5. Jusko W.J., Thomson A.W., Fung J., et al. Consensus document therapeutic monitoring of tacrolimus (FK506). Ther Drug Monit. 17:1995;606-614.
6. Jain A.B., Venkataramanan R., Cadoff E., et al. Effect of hepatic dysfunction and T tube clamping on FK506 pharmacokinetics and trough concentrations. Clin Pharmacol Ther. 57:1995;281-290.
7. Gonschior A., Christians U., Winkler M., et al. Tacrolimus (FK506) metabolite pattern in blood from liver and kidney transplant patients. Clin Chem. 42:1996;1426-1432.
8. Wallermacq P.E., Reding R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation clinical, biomedical and analytical aspects . Clin Chem. 39:1993;2219-2228.
9. Manuscript submitted. Yatscoff RW, Isotechnika Inc., Edmonton, Alberta, Canada.
10. Donnelly J.G., Soldin S.J. Partial characterization of a 52 kDa CsA/FK506/rapamycin binding protein. Clin Biochem. 27:1994;367-372.
11. Murthy J.N., Chen Y., Soldin S.J. Identification of a 14 kDa FK506/rapamycin binding immunophilin from Calf thymus. Clin Biochem. 27:1994;357-365.
12. Handschumaker RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific binding protein for cyclosporine A. Science 984; 226: 544-7.
13. Harding M.W., Galat A., Uehling D.E., Screiber S.L. A receptor for the immunosuppressant FK506 is cis-trans peptidyl-prolyl isomerase. Nature. 341:1989;758-760.
14. Murthy J.N., Goodyear N., Soldin S.J. Identification of a 37 kDa Tacrolimus, sirolimus and cyclosporine binding immunophilin processing glyceraldehyde 3 phosphate dehydrogenase activity from the Jurkat T-cell line. Clin Biochem. 30:1997;129-133.
15. Goodyear N., Napoli K.L., Murthy J.N., Kahan B., Soldin S.J. The 37 kDa immunophilin has uracil DNA glycosylase but not rotamase activity. Clin Biochem. 30:1997;497-499.
16. Murthy J.N., Chen Y., Warty V.S., et al. Radioreceptor assay for quantifying FK506 in whole blood. Clin Chem. 38:1992;1307-1310.
17. Goodyear N., Napoli K.L., Murthy J.N., Kahan B., Soldin S.J. Radioreceptor assay for sirolimus (rapamycin). Clin Biochem. 29:1996;458-460.
18. Wallemarcq P.E., Firdaous I., Hassoun A. Improvement and assessment of enzyme linked immunosorbant assay to detect low FK506 concentration in plasma or whole blood within 6 hours. Clin Chem. 39:1993;1045-1049.
19. Package insert 66-9474/R2. Abbott laboratories, Abbott Park, IL. USA.
20. Jusko W.J. Analysis of tacrolimus (FK506) in relation to therapeutic drug monitoring. Ther Drug Monit. 17:1995;596-601.
21. Tamura K., Fujimura T., Iwasaki K., et al. Interaction of tacrolimus (FK506) and its metabolites with FKBP and calcineurin. Biochem Biophys Res Commun. 202:1994;437-443.
22. Manuscript submitted. Yatscoff RW, Isotechnika Inc., Edmonton, Alberta, Canada.
23. Braun F., Schutz E., Christians U., et al. Pitfalls in monitoring tacrolimus (FK506). Ther Drug Monit. 19:1997;628-631.
24. Soldin S.J. Receptor assays in the clinical laboratory. Clin Biochem. 5:1996;439-444.
25. Soldin S.J. Receptor (immunophilin-binding) assay for immunosuppressive drugs. Ther Drug Monit. 17:1995;574-576.
26. Goodyear N., Murthy J.N., Gallant H.L., Yatscoff Y.W., Soldin S.J. Comparison of binding characteristics of four rapamycin metabolites to the 14 kDa and 52 kDa immunophilins to their pharmacological activity as measured in the MLC assay. Clin Biochem. 29:1996;309-313.